[
  {
    "ts": "2025-12-13T17:11:47+00:00",
    "headline": "Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?",
    "summary": "Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...",
    "url": "https://finance.yahoo.com/news/earlier-yescarta-lymphoma-altering-investment-171147958.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a20a8c41-c514-3069-bfef-625591ccc72f",
      "content": {
        "id": "a20a8c41-c514-3069-bfef-625591ccc72f",
        "contentType": "STORY",
        "title": "Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?",
        "description": "",
        "summary": "Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...",
        "pubDate": "2025-12-13T17:11:47Z",
        "displayTime": "2025-12-13T17:11:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/earlier-yescarta-lymphoma-altering-investment-171147958.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earlier-yescarta-lymphoma-altering-investment-171147958.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]